Vasopressors and low-flow states.
D000316:Adrenergic alpha-Agonists / Q000494:pharmacology; D000318:Adrenergic beta-Agonists / Q000494:pharmacology; D000818:Animals; D001775:Blood Circulation / Q000187:drug effects*; D002395:Catecholamines / Q000494:pharmacology; D004298:Dopamine / Q000494:pharmacology; D004837:Epinephrine / Q000494:pharmacology; D006706:Homeostasis / Q000187:drug effects; D006801:Humans; D007545:Isoproterenol / Q000494:pharmacology; D008833:Microcirculation / Q000187:drug effects; D009130:Muscle, Smooth / Q000187:drug effects; D009638:Norepinephrine / Q000494:pharmacology; D010455:Peptides / Q000494:pharmacology; D012769:Shock / Q000188:drug therapy; D013329:Structure-Activity Relationship; D013566:Sympathomimetics / Q000494:pharmacology; D014662:Vasoconstrictor Agents / Q000494:pharmacology* / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000494:pharmacology / Q000627:therapeutic use; D014667:Vasopressins / Q000494:pharmacology
D000316:Adrenergic alpha-Agonists; D000318:Adrenergic beta-Agonists; D002395:Catecholamines; D010455:Peptides; D013566:Sympathomimetics; D014662:Vasoconstrictor Agents; D014665:Vasodilator Agents; D014667:Vasopressins; D007545:Isoproterenol; D004298:Dopamine; D009638:Norepinephrine; D004837:Epinephrine